New combo therapy shows promise for rare, aggressive skin cancer
NCT ID NCT03921008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests giving the chemotherapy drug paclitaxel before and during radiation therapy for people with cutaneous angiosarcoma, a rare and aggressive skin cancer. The goal is to shrink the tumor before surgery and improve how long patients live without the cancer coming back. About 20 participants will receive the treatment and be followed for outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paclitaxel (chemotherapy) and radiation therapy
- What this could lead to
- If successful, this combination could become a standard treatment to control cutaneous angiosarcoma before surgery, potentially improving survival rates.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply broadly. Chemotherapy and radiation have significant side effects, and the cancer may still recur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.